Device: Desktop
|
Home
Innovation
Mission
Latest News
Meet Us
Management Team
Corporate Team
Key R&D Team
Board of Directors
Scientific Advisory Board
Science
Molecular Target
Mechanism of Action
Aelis Farma's Targets
Pipeline
AEF0117
AEF0217
New CB
1
-SSi
Partners
News
Contact
Investors
fr
Menu
Home
Meet Us
Science
Pipeline
Partners
News
Contact
Investors
Français
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
Opening
a new frontier
in pharmacology
A pipeline of pharmacological inhibitors
with a unique mechanism of action
Signaling Specific inhibitors
of the CB
1
(CB
1
-SSi)
Targeting disease states of the brain while preserving normal behavior
AEF0117 for cannabis related disorders
AEF0217 for the treatment of cognitive deficits
+
more info
Aelis Farma’s Mission
”
To combine the scientific breakthrough of CB
1
with innovative drug development to provide new effective and safe treatments for brain diseases with unmet medical needs.
“
Pier Vincenzo Piazza, CEO
Download our corporate presentation
+
more info
Latest News
Visite our news page
Latest News
Pier Vincenzo Piazza, CEO of Aelis Farma, receives the Distinguished Achievement Award from the European Behavioural Pharmacology Society (EBPS)
August 2023
+
Aelis Farma takes part in the 10th edition of the Gordon Research Conference on the role of cannabinoid receptors in central nervous system disorders
July 2023
+